Dillan DiNardo is the Co-Founder and CEO of Mindstate Design Labs, a psychedelic drug development company designing altered states of consciousness for use in mental health therapeutics. A biotechnology investor and operator with a background in venture capital, he has worked in a $1 billion venture fund, executing and managing more than fifty biopharma, medical device, and health tech investments ranging from pre-seed to publicly traded companies. In addition to his investing capacity, he took an operating role in over a dozen early-stage spinout companies. His experience spans a variety of disease indications and modalities, with a focus on deep-tech applications such as cell and gene therapies. Prior to his venture roles, he worked in finance for large international accounting and consulting firms as a transaction-focused consultant, covering the full investment cycle from seed-stage startup funding to Fortune 500 mergers, acquisitions, and divestitures.